Effects of perindopril on levels of endothelial dysfunction biomarkers in chronic heart failure patients with mid-range ejection fraction after 12-month therapy
Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy